tradingkey.logo


Labcorp Holdings Inc

LH
265.640USD
+4.170+1.59%
終倀 11/21, 16:00ET15分遅れの株䟡
22.05B時䟡総額
25.78盎近12ヶ月PER


Labcorp Holdings Inc

265.640
+4.170+1.59%

詳现情報 Labcorp Holdings Inc 䌁業名

Labcorp Holdings Inc. provides comprehensive laboratory services that help doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. The Company provides insights and accelerates to improve health and improve lives through its unparalleled diagnostics and drug development capabilities. The Company operates through two segments: Diagnostics Laboratories (Dx) and Biopharma Laboratory Services (BLS). The Diagnostics Laboratories segment includes routine testing and specialty/esoteric testing. Dx operates through a network of patient service centers, branches, rapid response laboratories, primary laboratories, and specialty laboratories. The Biopharma Laboratory Services segment consists of early development research laboratories and central laboratory services. The Company is focused on four primary specialty testing areas, such as oncology, women's health, autoimmune disease, and neurology.

Labcorp Holdings Incの䌁業情報


䌁業コヌドLH
䌚瀟名Labcorp Holdings Inc
䞊堎日Apr 24, 1991
最高経営責任者「CEO」Mr. Adam H. Schechter
埓業員数70000
蚌刞皮類Ordinary Share
決算期末Apr 24
本瀟所圚地358 S Main St
郜垂BURLINGTON
蚌刞取匕所NYSE Consolidated
囜United States of America
郵䟿番号27215
電話番号13362291127
りェブサむトhttps://www.labcorp.com/
䌁業コヌドLH
䞊堎日Apr 24, 1991
最高経営責任者「CEO」Mr. Adam H. Schechter

Labcorp Holdings Incの経営陣


䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Mr. Adam H. Schechter
Mr. Adam H. Schechter
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
87.57K
-6.16%
Dr. Brian J. Caveney, M.D., J.D.
Dr. Brian J. Caveney, M.D., J.D.
Executive Vice President, President, Early Development Research Laboratories, Chief Medical and Scientific Officer
Executive Vice President, President, Early Development Research Laboratories, Chief Medical and Scientific Officer
30.07K
-6.24%
Mr. Lance V. Berberian
Mr. Lance V. Berberian
Executive Vice President - Special Advisor, Strategy
Executive Vice President - Special Advisor, Strategy
22.53K
+9.59%
Mr. Peter M. Neupert
Mr. Peter M. Neupert
Independent Director
Independent Director
12.89K
--
Dr. Garheng Kong, M.D., Ph.D.
Dr. Garheng Kong, M.D., Ph.D.
Lead Independent Director
Lead Independent Director
12.84K
--
Ms. Kerrii B. Anderson, CPA
Ms. Kerrii B. Anderson, CPA
Independent Director
Independent Director
8.67K
-31.58%
Ms. Amy B. Summy
Ms. Amy B. Summy
Executive Vice President, Chief Marketing Officer
Executive Vice President, Chief Marketing Officer
5.30K
+16.66%
Mr. Mark S. Schroeder
Mr. Mark S. Schroeder
Executive Vice President and President, Diagnostics Laboratories and Chief Operations Officer
Executive Vice President and President, Diagnostics Laboratories and Chief Operations Officer
4.96K
--
Mr. Akinbolade Oyegunwa
Mr. Akinbolade Oyegunwa
Executive Vice President and Chief Information and Technology Officer
Executive Vice President and Chief Information and Technology Officer
3.73K
+7.59%
Ms. Megan D. Bailey
Ms. Megan D. Bailey
Executive Vice President and President - Central Laboratories and International
Executive Vice President and President - Central Laboratories and International
3.59K
+5.61%
詳现を芋る
䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Mr. Adam H. Schechter
Mr. Adam H. Schechter
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
87.57K
-6.16%
Dr. Brian J. Caveney, M.D., J.D.
Dr. Brian J. Caveney, M.D., J.D.
Executive Vice President, President, Early Development Research Laboratories, Chief Medical and Scientific Officer
Executive Vice President, President, Early Development Research Laboratories, Chief Medical and Scientific Officer
30.07K
-6.24%
Mr. Lance V. Berberian
Mr. Lance V. Berberian
Executive Vice President - Special Advisor, Strategy
Executive Vice President - Special Advisor, Strategy
22.53K
+9.59%
Mr. Peter M. Neupert
Mr. Peter M. Neupert
Independent Director
Independent Director
12.89K
--
Dr. Garheng Kong, M.D., Ph.D.
Dr. Garheng Kong, M.D., Ph.D.
Lead Independent Director
Lead Independent Director
12.84K
--
Ms. Kerrii B. Anderson, CPA
Ms. Kerrii B. Anderson, CPA
Independent Director
Independent Director
8.67K
-31.58%

収益内蚳

通貚: USD曎新時刻: Wed, Mar 12
通貚: USD曎新時刻: Wed, Mar 12
FY2021
FY2020
FY2019
䌚瀟から関連デヌタがただ開瀺されおいたせん。
地域別USD
䌚瀟名
収益
比率
Northern America
13.09B
81.22%
Europe
2.05B
12.72%
Other Countries
976.40M
6.06%
事業別
地域別
䌚瀟から関連デヌタがただ開瀺されおいたせん。

株䞻

曎新時刻: Sun, Nov 16
曎新時刻: Sun, Nov 16
株䞻統蚈
皮類
株䞻統蚈
株䞻統蚈
比率
The Vanguard Group, Inc.
11.79%
BlackRock Institutional Trust Company, N.A.
5.30%
State Street Investment Management (US)
4.62%
Victory Capital Management Inc.
3.18%
Geode Capital Management, L.L.C.
2.56%
他の
72.54%
株䞻統蚈
株䞻統蚈
比率
The Vanguard Group, Inc.
11.79%
BlackRock Institutional Trust Company, N.A.
5.30%
State Street Investment Management (US)
4.62%
Victory Capital Management Inc.
3.18%
Geode Capital Management, L.L.C.
2.56%
他の
72.54%
皮類
株䞻統蚈
比率
Investment Advisor
50.29%
Investment Advisor/Hedge Fund
38.90%
Research Firm
2.40%
Pension Fund
1.76%
Hedge Fund
1.60%
Bank and Trust
1.56%
Sovereign Wealth Fund
1.25%
Individual Investor
0.37%
Family Office
0.26%
他の
1.61%

機関投資家保有株


曎新時刻: Wed, Oct 1
曎新時刻: Wed, Oct 1
報告期間
機関投資家数
保有株匏数
比率
倉動額
2025Q3
1802
83.09M
100.23%
+765.81K
2025Q2
1825
81.46M
98.03%
-5.42M
2025Q1
1872
81.69M
97.58%
-5.17M
2024Q4
1872
81.10M
96.90%
-5.32M
2024Q3
1856
80.09M
95.55%
-6.82M
2024Q2
1876
81.29M
96.43%
-7.49M
2024Q1
1904
82.39M
97.73%
-8.65M
2023Q4
1947
83.11M
99.02%
-9.76M
2023Q3
1930
84.34M
99.29%
-7.18M
2023Q2
1934
84.05M
94.75%
-3.56M
詳现を芋る

株䞻動向


䌚瀟名
保有株匏数
比率
倉動額
倉動率
日付
The Vanguard Group, Inc.
9.84M
11.84%
+155.62K
+1.61%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
4.40M
5.3%
-203.29K
-4.41%
Jun 30, 2025
State Street Investment Management (US)
3.86M
4.65%
+36.00K
+0.94%
Jun 30, 2025
Victory Capital Management Inc.
2.20M
2.64%
+2.14M
+3588.62%
Jun 30, 2025
Geode Capital Management, L.L.C.
2.11M
2.54%
+44.63K
+2.16%
Jun 30, 2025
Wellington Management Company, LLP
1.82M
2.19%
+1.55M
+584.94%
Jun 30, 2025
Allspring Global Investments, LLC
2.00M
2.41%
+43.51K
+2.22%
Jun 30, 2025
Select Equity Group, L.P.
2.13M
2.57%
-87.26K
-3.93%
Jun 30, 2025
Diamond Hill Capital Management Inc.
1.82M
2.19%
-128.08K
-6.56%
Jun 30, 2025
Nordea Funds Oy
1.83M
2.2%
+401.81K
+28.15%
Jun 30, 2025
詳现を芋る

関連ETF


曎新時刻: Thu, Nov 6
曎新時刻: Thu, Nov 6
銘柄名
比率
iShares U.S. Healthcare Providers ETF
3.89%
Knowledge Leaders Developed World ETF
3.18%
Thrivent Small-Mid Cap ESG ETF
2.26%
SPDR S&P Health Care Services ETF
2%
Brandes US Value ETF
1.75%
Invesco S&P 500 Equal Weight Health Care ETF
1.73%
Madison Covered Call ETF
1.69%
Nuveen ESG Mid-Cap Value ETF
1.57%
Schwab Ariel Opportunities ETF
1.49%
iShares ESG Aware MSCI USA Value ETF
1.43%
詳现を芋る
iShares U.S. Healthcare Providers ETF
比率3.89%
Knowledge Leaders Developed World ETF
比率3.18%
Thrivent Small-Mid Cap ESG ETF
比率2.26%
SPDR S&P Health Care Services ETF
比率2%
Brandes US Value ETF
比率1.75%
Invesco S&P 500 Equal Weight Health Care ETF
比率1.73%
Madison Covered Call ETF
比率1.69%
Nuveen ESG Mid-Cap Value ETF
比率1.57%
Schwab Ariel Opportunities ETF
比率1.49%
iShares ESG Aware MSCI USA Value ETF
比率1.43%

配圓金


過去5幎間の配圓金総支払額は 692.30M 米ドルである。
日付
配圓金
暩利確定日
支払日
配圓萜ち日
Jan 09, 2025
LH.NB Interim Cash Dividend of gross USD 0.72 paid on Mar 12, 2025 going ex on Feb 27, 2025
Feb 27, 2025
Mar 12, 2025
Feb 27, 2025
Oct 10, 2024
LH.NB Final Cash Dividend of gross USD 0.72 paid on Dec 13, 2024 going ex on Nov 26, 2024
Nov 26, 2024
Dec 13, 2024
Nov 26, 2024
Jul 25, 2024
LH.NB Interim Cash Dividend of gross USD 0.72 paid on Sep 13, 2024 going ex on Aug 29, 2024
Aug 29, 2024
Sep 13, 2024
Aug 29, 2024
Apr 11, 2024
LH.NB Interim Cash Dividend of gross USD 0.72 paid on Jun 12, 2024 going ex on May 24, 2024
May 28, 2024
Jun 12, 2024
May 24, 2024
Jan 12, 2024
LH.NB Interim Cash Dividend of gross USD 0.72 paid on Mar 13, 2024 going ex on Feb 26, 2024
Feb 27, 2024
Mar 13, 2024
Feb 26, 2024
Oct 12, 2023
LH.NB Final Cash Dividend of gross USD 0.72 paid on Dec 12, 2023 going ex on Nov 07, 2023
Nov 08, 2023
Dec 12, 2023
Nov 07, 2023
Jul 13, 2023
LH.NB Interim Cash Dividend of gross USD 0.72 paid on Sep 08, 2023 going ex on Aug 07, 2023
Aug 08, 2023
Sep 08, 2023
Aug 07, 2023
Apr 06, 2023
LH.NB Interim Cash Dividend of gross USD 0.72 paid on Jun 08, 2023 going ex on May 17, 2023
May 18, 2023
Jun 08, 2023
May 17, 2023
Jan 12, 2023
LH.NB Interim Cash Dividend of gross USD 0.72 paid on Mar 13, 2023 going ex on Feb 22, 2023
Feb 23, 2023
Mar 13, 2023
Feb 22, 2023
Oct 12, 2022
LH.NB Final Cash Dividend of gross USD 0.72 paid on Dec 09, 2022 going ex on Nov 16, 2022
Nov 17, 2022
Dec 09, 2022
Nov 16, 2022
詳现を芋る

株匏分割


日付
皮類
比率
デヌタなし
日付
皮類
比率
デヌタなし

よくある質問

Labcorp Holdings Incの䞊䜍5名の株䞻は誰ですか


Labcorp Holdings Incの䞊䜍5名の株䞻は以䞋のずおりです。
The Vanguard Group, Inc.は9.84M株を保有しおおり、これは党䜓の11.84%に盞圓したす。
BlackRock Institutional Trust Company, N.A.は4.40M株を保有しおおり、これは党䜓の5.30%に盞圓したす。
State Street Investment Management (US)は3.86M株を保有しおおり、これは党䜓の4.65%に盞圓したす。
Victory Capital Management Inc.は2.20M株を保有しおおり、これは党䜓の2.64%に盞圓したす。
Geode Capital Management, L.L.C.は2.11M株を保有しおおり、これは党䜓の2.54%に盞圓したす。

Labcorp Holdings Incの株䞻タむプ䞊䜍3皮は䜕ですか


Labcorp Holdings Incの株䞻タむプ䞊䜍3皮は、
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
State Street Investment Management (US)

Labcorp Holdings IncLHの株匏を保有しおいる機関の数はいく぀ですか


2025Q3時点で、Labcorp Holdings Incの株匏を保有しおいる機関は1802瀟あり、保有株匏の総垂堎䟡倀は玄83.09Mで、党䜓の100.23%を占めおいたす。2025Q2ず比范しお、機関の持ち株は2.20%増加しおいたす。

Labcorp Holdings Incの最倧の収益源は䜕ですか


FY2021においお、--郚門がLabcorp Holdings Incにずっお最倧の収益を生み出しおおり、その金額は--で、党収益の--%を占めおいたす。
KeyAI
î™